285 related articles for article (PubMed ID: 23051684)
1. Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients.
Han HJ; Kim BC; Lee JY; Ryu SH; Na HR; Yoon SJ; Park HY; Shin JH; Cho SJ; Yi HA; Choi MS; Heo JH; Park KW; Kim KK; Choi SH
Dement Geriatr Cogn Disord; 2012; 34(3-4):167-73. PubMed ID: 23051684
[TBL] [Abstract][Full Text] [Related]
2. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
3. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
[TBL] [Abstract][Full Text] [Related]
4. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
[TBL] [Abstract][Full Text] [Related]
5. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
Articus K; Baier M; Tracik F; Kühn F; Preuss UW; Kurz A
Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184
[TBL] [Abstract][Full Text] [Related]
6. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment.
Dantoine T; Auriacombe S; Sarazin M; Becker H; Pere JJ; Bourdeix I
Int J Clin Pract; 2006 Jan; 60(1):110-8. PubMed ID: 16409439
[TBL] [Abstract][Full Text] [Related]
7. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
[TBL] [Abstract][Full Text] [Related]
8. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.
Visser PJ; Scheltens P; Pelgrim E; Verhey FR;
Dement Geriatr Cogn Disord; 2005; 19(2-3):126-33. PubMed ID: 15627759
[TBL] [Abstract][Full Text] [Related]
9. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study.
Choi SH; Park KW; Na DL; Han HJ; Kim EJ; Shim YS; Lee JH;
Curr Med Res Opin; 2011 Jul; 27(7):1375-83. PubMed ID: 21561398
[TBL] [Abstract][Full Text] [Related]
10. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.
Grossberg GT; Olin JT; Somogyi M; Meng X
Int J Clin Pract; 2011 Apr; 65(4):465-71. PubMed ID: 21309961
[TBL] [Abstract][Full Text] [Related]
11. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
Farlow MR; Alva G; Meng X; Olin JT
Curr Med Res Opin; 2010 Feb; 26(2):263-9. PubMed ID: 19929593
[TBL] [Abstract][Full Text] [Related]
12. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
[TBL] [Abstract][Full Text] [Related]
13. Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer's disease.
Han HJ; Kwon JC; Kim JE; Kim SG; Park JM; Park KW; Park KC; Park KH; Moon SY; Seo SW; Choi SH; Cho SJ
Eur Neurol; 2015; 73(1-2):23-8. PubMed ID: 25376930
[TBL] [Abstract][Full Text] [Related]
14. Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers.
Farlow M; Lane R; Kudaravalli S; He Y
Pharmacogenomics J; 2004; 4(5):332-5. PubMed ID: 15289797
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses.
Alva G; Grossberg GT; Schmitt FA; Meng X; Olin JT
Int J Geriatr Psychiatry; 2011 Apr; 26(4):356-63. PubMed ID: 21312297
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C
Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669
[TBL] [Abstract][Full Text] [Related]
17. Relationship between the efficacy of rivastigmine and apolipoprotein E (epsilon4) in patients with mild to moderately severe Alzheimer disease.
Blesa R; Aguilar M; Casanova JP; Boada M; Martínez S; Alom J; de la Hoz CH; Sancho J; Fernández O; Gil-Neciga E; Massó JF
Alzheimer Dis Assoc Disord; 2006; 20(4):248-54. PubMed ID: 17132969
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32).
Olin JT; Bhatnagar V; Reyes P; Koumaras B; Meng X; Brannan S
Int J Geriatr Psychiatry; 2010 Apr; 25(4):419-26. PubMed ID: 19670390
[TBL] [Abstract][Full Text] [Related]
19. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
[TBL] [Abstract][Full Text] [Related]
20. Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factor.
Grossberg GT; Farlow MR; Meng X; Velting DM
Curr Alzheimer Res; 2015; 12(1):53-60. PubMed ID: 25523430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
